Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HCC1428 | HR+ | Luminal | Selumetinib | MEK | MAPK | 0.016 | uM | 10693.146 | 0.9742 | 0.9417 | 0.8826 | |
| HCC1428 | HR+ | Luminal | Selumetinib | MEK | MAPK | 0.08 | uM | 10693.146 | 0.9845 | 0.9648 | 0.8826 | |
| HCC1428 | HR+ | Luminal | Selumetinib | MEK | MAPK | 0.4 | uM | 10693.146 | 0.9625 | 0.9153 | 0.8826 | |
| HCC1428 | HR+ | Luminal | Selumetinib | MEK | MAPK | 2 | uM | 10693.146 | 0.9869 | 0.9704 | 0.8826 | |
| HCC1428 | HR+ | Luminal | Selumetinib | MEK | MAPK | 10 | uM | 10693.146 | 0.9988 | 0.9972 | 0.8826 | |
| HCC1428 | HR+ | Luminal | Selumetinib | MEK | MAPK | 50 | uM | 10693.146 | 0.9269 | 0.8351 | 0.8826 | |
| HCC1428 | HR+ | Luminal | Selumetinib | MEK | MAPK | 0.000128 | uM | 11936.155 | 0.9799 | 0.9455 | 0.7332 | |
| HCC1428 | HR+ | Luminal | Selumetinib | MEK | MAPK | 0.00064 | uM | 11936.155 | 0.9462 | 0.8547 | 0.7332 | |
| HCC1428 | HR+ | Luminal | Selumetinib | MEK | MAPK | 0.0032 | uM | 11936.155 | 1.0873 | 1.2420 | 0.7332 | |
| HCC1428 | HR+ | Luminal | Selumetinib | MEK | MAPK | 0.016 | uM | 11936.155 | 1.0463 | 1.1274 | 0.7332 | |
| HCC1428 | HR+ | Luminal | Selumetinib | MEK | MAPK | 0.08 | uM | 11936.155 | 1.0153 | 1.0417 | 0.7332 | |
| HCC1428 | HR+ | Luminal | Selumetinib | MEK | MAPK | 0.4 | uM | 11936.155 | 1.0635 | 1.1753 | 0.7332 | |
| HCC1428 | HR+ | Luminal | Selumetinib | MEK | MAPK | 2 | uM | 11936.155 | 0.9806 | 0.9473 | 0.7332 | |
| HCC1428 | HR+ | Luminal | Selumetinib | MEK | MAPK | 10 | uM | 11936.155 | 1.0173 | 1.0472 | 0.7332 | |
| HCC1428 | HR+ | Luminal | Selumetinib | MEK | MAPK | 50 | uM | 11936.155 | 1.0499 | 1.1374 | 0.7332 | |
| HCC1569 | HER2amp | Basal A | Selumetinib | MEK | MAPK | 0.000128 | uM | 10872.155 | 0.9931 | 0.9909 | 1.5288 | |
| HCC1569 | HER2amp | Basal A | Selumetinib | MEK | MAPK | 0.00064 | uM | 10872.155 | 0.9912 | 0.9885 | 1.5288 | |
| HCC1569 | HER2amp | Basal A | Selumetinib | MEK | MAPK | 0.0032 | uM | 10872.155 | 1.0421 | 1.0547 | 1.5288 | |
| HCC1569 | HER2amp | Basal A | Selumetinib | MEK | MAPK | 0.016 | uM | 10872.155 | 1.0196 | 1.0256 | 1.5288 | |
| HCC1569 | HER2amp | Basal A | Selumetinib | MEK | MAPK | 0.08 | uM | 10872.155 | 0.9763 | 0.9689 | 1.5288 | |
| HCC1569 | HER2amp | Basal A | Selumetinib | MEK | MAPK | 0.4 | uM | 10872.155 | 1.0007 | 1.0010 | 1.5288 | |
| HCC1569 | HER2amp | Basal A | Selumetinib | MEK | MAPK | 2 | uM | 10872.155 | 0.9301 | 0.9074 | 1.5288 | |
| HCC1569 | HER2amp | Basal A | Selumetinib | MEK | MAPK | 10 | uM | 10872.155 | 1.0977 | 1.1257 | 1.5288 | |
| HCC1569 | HER2amp | Basal A | Selumetinib | MEK | MAPK | 50 | uM | 10872.155 | 0.9732 | 0.9648 | 1.5288 | |
| HCC1569 | HER2amp | Basal A | Selumetinib | MEK | MAPK | 0.000128 | uM | 12523.155 | 1.0038 | 1.0072 | 1.0583 |